Drug Profile
Fostroxacitabine bralpamide - Medivir AB
Alternative Names: Fostrox; MIV-818Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Medivir AB
- Class Antineoplastics; Bromobenzenes; Dioxolanes; Esters; Nucleotides; Organophosphorus compounds; Pyrimidines; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 23 Apr 2024 Medivir provides an update from a Type C meeting with the US FDA, regarding the company's plans for a global phase IIb study
- 23 Apr 2024 Medivir plans a phase IIb trial for Liver cancer (Second-line therapy or greater, Combination therapy) in 2025
- 22 Feb 2024 Pharmacokinetics data from a phase I/IIa X trial in Liver cancer released by Medivir AB